Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.
about
Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancersPaclitaxel-induced cell death: where the cell cycle and apoptosis come together.Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteinsInhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways.Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferationEnhancement of the activity of phenoxodiol by cisplatin in prostate cancer cellsLoss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.MAP Kinases and Prostate Cancer.Drug discovery in advanced prostate cancer: translating biology into therapy.Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity.Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction.Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action.Quinacrine induces cytochrome c-dependent apoptotic signaling in human cervical carcinoma cells.Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine.Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition.
P2860
Q28743513-CC395DEA-07C8-42A1-81C6-3A8C8D2B7E8EQ33947088-15B5ADA7-4C5E-4504-B7BB-88646F0CCDA8Q35264079-33E0C1D3-D287-4CF5-9E67-8112FC4650D4Q36124790-E6C0D585-3115-4415-9B8B-95673FF105D8Q36264601-F31F9935-5E9A-4AEB-B151-12BD5E3966CBQ37123431-0C64ED76-35CD-451E-BA27-111A6495EA96Q37627650-EC779808-AFF1-447E-8ADC-85050BA4D6DAQ38791344-697049B6-000F-49F6-83ED-21255C37E230Q38839110-33B0A322-F4BE-4012-A3A0-FC6B7F0E5376Q39547659-53C2918D-B424-46C2-AD7E-573206D57BD1Q40139186-D85818F7-9E94-4483-B656-11C656DAE324Q40411377-E39D2F54-73EF-4472-8CA2-7211CCF548B9Q42479121-581C388C-05DF-472A-9028-19FDD0E40D1FQ43599105-8225DD09-4EDE-4FC1-86A3-A26AD358BFCAQ46427682-7D7AC914-779F-4CA2-86D4-32447C8CD5FEQ55110970-B348FFAD-11EA-40A5-859C-A1663745B8D5
P2860
Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Enhancement of paclitaxel acti ...... tro and in vivo by quinacrine.
@ast
Enhancement of paclitaxel acti ...... tro and in vivo by quinacrine.
@en
type
label
Enhancement of paclitaxel acti ...... tro and in vivo by quinacrine.
@ast
Enhancement of paclitaxel acti ...... tro and in vivo by quinacrine.
@en
prefLabel
Enhancement of paclitaxel acti ...... tro and in vivo by quinacrine.
@ast
Enhancement of paclitaxel acti ...... tro and in vivo by quinacrine.
@en
P2093
P2860
P356
P1476
Enhancement of paclitaxel acti ...... tro and in vivo by quinacrine.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1997.272
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1031413235